Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 106
- Registration Number
- NCT00735007
- Locations
- 🇩🇪
Germany, Local Medical Information, Hamburg, Ulm, Berlin, Erbach, Germany
🇸🇪Sweden, Local Medical Information, Sweden, Sweden
🇨🇦Canada, Local Medical Information, Ontario, British Columbia, Quebec, Canada
Oral Cladribine in Early Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2021-03-22
- Target Recruit Count
- 617
- Registration Number
- NCT00725985
- Locations
- 🇺🇸
Multiple Sclerosis Center Drive, Neurology Suite 701, Newport Beach, California, United States
🇺🇸MS Center of Brevard MIMA Centry Research Associates, Melbourne, Florida, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00676715
- Locations
- 🇺🇸
Phoenix Neurological Associates Ltd, Phoenix, Arizona, United States
🇧🇬CCB Medical institute, Ministry of Interior Sofia; CLINIC OF NEUROLOGY, Sofia, Bulgaria
🇺🇸MS Center of Vero Beach, Vero Beach, Florida, United States
Transition to Rebif New Formulation
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 117
- Registration Number
- NCT00619307
- Locations
- 🇩🇪
Local Medical Information, Munich, Germany
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1331
- Registration Number
- NCT00605215
- Locations
- 🇺🇸
Teva Investigational Site 1263, Shreveport, Louisiana, United States
🇷🇴Teva Investigational Site 5219, Sibiu, Romania
🇩🇪Teva Investigational Site 6402, Berlin, Germany
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 136
- Registration Number
- NCT00599274
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
🇨🇦Coordinating Research Site, Halifax, Nova Scotia, Canada
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2008-09-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 19
- Registration Number
- NCT00574041
- Locations
- 🇦🇺
Coordinating Research Site, Malvern, Victoria, Australia
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 284
- Registration Number
- NCT00534261
- Locations
- 🇬🇧
Coordinating Research Site, Glasgow, Scotland, United Kingdom
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 43
- Registration Number
- NCT00501943
- Locations
- 🇺🇸
UCSF MS Center , 675 Nelson Rising Lane, Suite 221, San Francisco, California, United States
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00493116
- Locations
- 🇳🇿
Research Site, Hamilton, New Zealand
🇦🇺Coordinating Research Site, NSW, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.